TScan Therapeutics (TCRX) Times Interest Earned (2020 - 2026)
TScan Therapeutics (TCRX) posted quarterly Times Interest Earned of -$42.29 for Q1 2026, up 20.78% year-over-year from -$35.01 in Q1 2025, and down 24.44% quarter-over-quarter from -$33.99 in Q4 2025.
TScan Therapeutics (TCRX) Times Interest Earned (2020 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has reported Times Interest Earned for 7 consecutive years, with -$42.29 the latest figure, recorded in Q1 2026.
- In Q1 2026, Times Interest Earned rose 20.78% year-over-year to -$42.29; the TTM figure through Mar 2026 stood at -$46.31 (down 11.82% YoY), while the FY2025 annual figure was -$1.62, up 88.25% from the prior year.
- Times Interest Earned declined to -$42.29 in Q1 2026 per TCRX's latest filing, from -$33.99 in the prior quarter.
- Across five years, Times Interest Earned topped out at -$10.37 in Q4 2022 and bottomed at -$82.48 in Q3 2022.
- Historically, Times Interest Earned has averaged -$37.98 across 5 years, with a median of -$34.05 in 2024.
- Annual changes were most pronounced in 2022 — Times Interest Earned plunged 4820.96% — and 2023, when it soared 69.44%.
- TScan Therapeutics' Times Interest Earned stood at -$10.37 in 2022, then sank by 37.53% to -$14.26 in 2023, then slumped by 228.45% to -$46.83 in 2024, then advanced by 27.42% to -$33.99 in 2025, then fell by 24.44% to -$42.29 in 2026.
- Business Quant data shows TCRX's Times Interest Earned at -$42.29 in Q1 2026, -$33.99 in Q4 2025, and -$53.01 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | TScan Therapeutics | 100.62 Mn | 100.62 Mn | - | -43.62 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -43.62 |
| Mar 31, 2026 | -42.29 |
| Dec 31, 2025 | -33.99 |
| Sep 30, 2025 | -53.01 |
| Jun 30, 2025 | -56.10 |
| Mar 31, 2025 | -53.39 |
| Dec 31, 2024 | -46.83 |
| Sep 30, 2024 | -34.05 |
| Jun 30, 2024 | -35.83 |
| Mar 31, 2024 | -32.71 |
| Dec 31, 2023 | -14.26 |
| Sep 30, 2023 | -25.20 |
| Jun 30, 2023 | -25.40 |
| Mar 31, 2023 | -23.79 |
| Dec 31, 2022 | -10.37 |
| Sep 30, 2022 | -82.48 |
| Dec 31, 2021 | -20.64 |
| Sep 30, 2021 | -1.68 |
| Jun 30, 2021 | -0.48 |
| Dec 31, 2020 | -11.76 |